Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 05, 2022 08:05 ET
|
Lyell Immunopharma, Inc
Five poster presentations to include preclinical data describing new T-cell reprogramming technology being incorporated in LYL119, Lyell’s next product candidate SOUTH SAN FRANCISCO, Calif., Oct. ...
Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer
September 28, 2022 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies...
Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022
September 12, 2022 03:00 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies...
Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference
August 30, 2022 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies...
Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights
August 04, 2022 16:05 ET
|
Lyell Immunopharma, Inc
Cash, cash equivalents and marketable securities of $787.0 million as of June 30, 2022 provides funding into 2025 and supports advancement of multiple product candidates through key clinical...
Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference
June 07, 2022 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies...
Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights
May 10, 2022 16:05 ET
|
Lyell Immunopharma, Inc
Cash, cash equivalents and marketable securities of $838 million as of March 31, 2022 supports advancing a robust cell therapy pipelineResearch highlighting novel reprogramming technologies designed...
Lyell Immunopharma to Participate in BofA Securities Healthcare Conference
May 04, 2022 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid...
Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical Development at ASGCT Annual Meeting
May 02, 2022 16:30 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid...
Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
March 29, 2022 16:05 ET
|
Lyell Immunopharma, Inc
Cash, cash equivalents and marketable securities of $898 million as of December 31, 2021 supports advancing multi-modality cell therapy pipelineClinical development commencing for two programs that...